Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.58 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | BLK | P51451 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17623686 | 0.89 | STK17B (0.59) | STK17BSTK17ANAAAALDH1A1KMT2A | |
| SCHEMBL17623516 | 0.88 | STK17B (0.58) | STK17BSTK17ACYP1A2CYP2C19KMT2A | |
| SCHEMBL17623510 | 0.87 | STK17B (0.57) | STK17BSTK17AKMT2AJAK1BLK | |
| SCHEMBL19160033 | 0.87 | STK17B (0.60) | STK17BSTK17AALDH1A1KMT2AJAK1 | |
| SCHEMBL17623685 | 0.87 | STK17B (0.60) | STK17BSTK17AALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL17623633 | 0.87 | STK17B (0.57) | STK17BSTK17AKMT2AJAK1BLK | |
| SCHEMBL17623680 | 0.85 | STK17B (0.57) | STK17BSTK17AKMT2AJAK1BLK | |
| SCHEMBL19160295 | 0.84 | STK17B (0.54) | STK17BSTK17AKMT2AJAK1BLK | |
| SCHEMBL19160503 | 0.84 | STK17B (0.56) | STK17BSTK17AKMT2AJAK1BLK | |
| SCHEMBL17623585 | 0.84 | JAK1 (0.55) | STK17BSTK17ACFTRJAK1BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196194-B1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE JAK3 AND/OR JAK1 INHIBITORS | SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| EP-3196194-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | Shenzhen Chipscreen Biosciences, Ltd. (CN) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016041472-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | 深圳微芯生物科技有限责任公司 | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011571-B2 | Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound | JAK3, JAK1, JAK2 | STK17B 124/4885STK17A 59/4885NAAA 2788/4885 |
| US-20170253566-A1 | PREPARATION METHOD FOR AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE JAK3 AND/OR JAK1 KINASE INHIBITOR AND APPLICATION OF AROMATIC HETEROCYCLIC COMPOUND | JAK3, JAK1, JAK2 | STK17B 124/4885STK17A 59/4885NAAA 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.